713791
O,O′-Bis[2-(N-Succinimidyl-succinylamino)ethyl]polyethylene glycol
10,000
Sinónimos:
Polyethylene glycol, α,ω-Bis-NHS-PEG, Di(N-succinimidyl) PEG-diacid, PEG-bis(N-succinimidyl succinate)
About This Item
Productos recomendados
![O,O′-Bis[2-(N-Succinimidyl-succinylamino)ethyl]polyethylene glycol 2,000](/deepweb/assets/sigmaaldrich/product/structures/161/408/20f7ade0-3e2e-4861-ae89-3d81c050059a/640/20f7ade0-3e2e-4861-ae89-3d81c050059a.png)
![O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol Mw 5000](/deepweb/assets/sigmaaldrich/product/structures/271/277/d02536f0-83d7-4416-9cea-f6213e09fe85/640/d02536f0-83d7-4416-9cea-f6213e09fe85.png)
Quality Level
form
lumps
mol wt
average Mn 10,000
reaction suitability
reagent type: cross-linking reagent
Ω-end
NHS ester
α-end
NHS ester
storage temp.
−20°C
¿Está buscando productos similares? Visita Guía de comparación de productos
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Artículos
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico